Phase I study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid …

…, A Tsuhako, K Morrissey, S Mahrus, R Morley… - Clinical Cancer …, 2019 - AACR
Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion
and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing …

British Association of Urological Surgeons' suprapubic catheter practice guidelines

SCW Harrison, WT Lawrence, R Morley… - BJU …, 2011 - Wiley Online Library
What’s known on the subject? and What does the study add? The suprapubic catheter (SPC)
is a useful and widely used tool in urological practice. However, complications can arise …

Long‐term follow‐up of a multicentre randomised controlled trial comparing tension‐free vaginal tape, xenograft and autologous fascial slings for the treatment of …

ZA Khan, A Nambiar, R Morley, CR Chapple… - BJU …, 2015 - Wiley Online Library
Objective To compare the long‐term outcomes of a tension‐free vaginal tape ( TVT ; G
ynecare™, S omerville, NJ , USA ), autologous fascial sling ( AFS ) and xenograft sling (porcine …

Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity

…, F Lee, K Wang, L Williams, R Morley - BJU …, 2007 - Wiley Online Library
OBJECTIVES To evaluate the efficacy and complications of botulinum A toxin (Dysport, Ipsen
Ltd, Slough, UK) 500 U in refractory idiopathic detrusor overactivity (IDO). PATIENTS AND …

Clinical and patient-reported outcome measures in men referred for consideration of surgery to treat lower urinary tract symptoms: baseline results and diagnostic …

…, RG Mason, E McLarty, V Mishra, J Mom, R Morley… - European urology …, 2019 - Elsevier
Background Clinical evaluation of male lower urinary tract symptoms (MLUTS) in secondary
care uses a range of assessments. It is unknown how MLUTS evaluation influences …

What patients think: patient-reported outcomes of retropubic versus trans-obturator mid-urethral slings for urodynamic stress incontinence—a multi-centre randomised …

…, P Smith, M James, A Sultan, R Morley… - International …, 2011 - Springer
Introduction and hypothesis The purpose of this study is to determine if the trans-obturator
tape (TOT; Monarc, American Medical Systems (AMS)), which has been claimed to have …

GDC-0810 pharmacokinetics and transporter-mediated drug interaction evaluation with an endogenous biomarker in the first-in-human, dose escalation study

…, K Yoshida, S Cheeti, B Chen, R Morley… - Drug Metabolism and …, 2019 - ASPET
GDC-0810 ( Cheeti et al., 2018 ) is an orally bioavailable, selective estrogen receptor (ER)
degrader developed to treat ER-positive breast cancer. A first-in-human (FIH) dose escalation …

Effect of OATP1B1/1B3 inhibitor GDC‐0810 on the pharmacokinetics of pravastatin and coproporphyrin I/III in healthy female subjects

…, B Chen, M Gates, S Singel, R Morley… - The Journal of …, 2018 - Wiley Online Library
Developed as an oral anticancer drug to treat estrogen receptor–positive breast cancer,
GDC‐0810 was shown to be a potent inhibitor of organic anion‐transporting polypeptide 1B1 …

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with …

…, JM Spoerke, C Metcalfe, L Liu, R Li, R Morley… - Cancer research, 2018 - AACR
Background: Modulation of estrogen activity and/or synthesis is the mainstay therapeutic
strategy in the treatment of ER+ BC. However, despite the effectiveness of available endocrine …

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid …

…, L Mueller, R Lin, K Morrissey, S Mahrus, R Morley… - 2017 - ascopubs.org
105 Background: GDC-0919, a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1),
reduces tryptophan catabolism and kynurenine production within the tumor …